The differences in disease progression between DMD and BMD form the basis of potential therapeutic interventions using antisense oligomers (AOs) that aim to induce exon skipping and generate a BMD-like dystrophin isoform from a DMD-mutated dystrophin gene [8,9,10]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.